0 Items - $0.00
Categories
A to Z

Alternative structural projections:

6-MBC-cAMP

N6- Mono- t. butylcarbamoyladenosine- 3', 5'- cyclic monophosphate, sodium salt (6-MBC-cAMP)

Membrane-permeant, site-selective PKA agonist
Cat. No.: M 012
    
CAS No.: [84433-46-5]
Shipping: ambient
Product Name Price (net) Qty
Cat. No.: M 012-05
Unit: 5 µmol / ~2.3 mg
$88.00
For other salt forms please inquire. Site selective activator of protein kinase A ( cyclic AMP agonist ) strongly preferring the A site of cAK II. Together with e.g. Sp-5,6-DCl-cBIMPS (Cat. No. D 014) selective stimulation of type II can be achieved. 6-MBC-cAMP is considered not to activate Epac. Detailed technical information and updated reference list available on request. References: Maronde et al., J. Pineal Res., 27, 170 - 182 (1999); Fricke et al., Endocrinology, 145, 4940 - 4947 (2004).
Cat. No. M 012
CAS number [84433-46-5]
Purity > 98% HPLC
Salt form Sodium
Storage temperature -20°C / -4°F
Molecular formula C₁₅H₂₀N₆O₇P · Na
Molecular weight [g/mol] 450,3
Target PKA (cAK) Activator
Lipophilicity 2.67
Absorption max [nm] 268
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] 23700
  • 1. Gausdal G., Wergeland A., Skavland J., Nguyen E., Pendino F., Rouhee N., McCormack E., Herfindal L., Kleppe R., Havemann U., Schwede F., Bruseud O., Gjertsen B. T., Lanotte M., Segal-Bendirdjian E.Doskeland S. O., Cell Death Dis., 4, 0 - 0 (2013), "Cyclic AMP Can Promote APL Progression and Protect Myeloid Leukemia Cells Against Anthracycline-Induced Apoptosis"
  • 2. Huseby S., Gausdal G., Keen T. J., Kjærland E., Krakstad C., Myhren L., Brønstad K., Kunick C., Schwede F., Genieser H.-G., Kleppe R.Doeskeland S. O., Cell Death Dis., e237, 2, 0 - 0 (2011), "Cyclic AMP Induces IPC Leukemia Cell Apoptosis via CRE-and CDK-dependent Bim Transcription"
  • 3. Schweinsberg S., Moll D., Burghardt N. C., Hahnefeld C., Schwede F., Zimmermann B., Drewianka S., Werner L., Kleinjung F., Genieser H.-G., Schuchhardt J.Herberg F. W., Proteomics, 8, 1212 - 1220 (2008), "Systematic interpretation of cyclic nucleotide binding studies using KinetXBase"
  • 4. Nguyen G. H., French R.Radhakrishna H., Cell Signal., 16, 1141 - 1151 (2004), "Protein Kinase A Inhibits Lysophosphatidic Acid Induction of Serum Response Factor via Alterations in the Actin Cytoskeleton"
  • 5. Fricke K., Heitland A.Maronde E., Endocrinology, 145, 4940 - 4947 (2004), "Cooperative Activation of Lipolysis by Protein Kinase A and Protein Kinase C Pathways in 3T3-L1 Adipocytes"
  • 6. Kopperud R. K., Krakstad C., Selheim F.Doeskeland S. O., FEBS Lett., 546, 121 - 126 (2003), "cAMP Effector Mechanisms. Novel Twists for an 'Old' Signaling System"
  • 7. Christensen A. E.Doeskeland S. O., Handbook of Cell Signaling Academic Press/Elsevier Science San Diego CA, 2, 549 - 554 (2003), "Cyclic Nucleotide Analogs as Tools to Investigate Cyclic Nucleotide Signaling"
  • 8. Hahnefeld C.Herberg F. W., Abstract of the 13th Protein Kinase Symposium p. 14, 0, 12 - 15 (2002), "cAMP-dependent Protein Kinase: cAMP Analog Screening Using Surface Plasmon Resonance and Fluorescent Methods"
  • 9. Osinski M., Ph.D. Thesis Düsseldorf/Germany, 0, 0 - 0 (2000), "Pharmakologische Ansätze einer Proteinkinase A-Aktivierung zur Hemmung der Mitogenese glatter Gefäßmuskelzellen"
  • 10. Pfeffer M., Maronde E., Korf H.-W.Stehle J. H., J. Pineal Res., 29, 24 - 33 (2000), "Antisense Experiments Reveal Molecular Details on Mechanism of ICER Suppressing cAMP-inducible Genes in Rat Pinealocytes"
  • 11. Pfeffer M., Maronde E., Molina C. A., Korf H.-W.Stehle J. H., Mol. Pharmacol., 56, 279 - 289 (1999), "Inducible cyclic AMP early repressor protein in rat pinealocytes: A highly sensitive natural reporter for regulated gene transcription"
  • 12. Maronde E., Wicht H., Tasken K., Genieser H.-G., Dehghani F., Olcese J.Korf H.-W., J. Pineal Res., 27, 170 - 182 (1999), "CREB Phosphorylation and Melatonin Biosynthesis in the Rat Pineal Gland: Involvement of cyclic AMP-dependent Protein KinaseType II"
  • 13. Pfeifer A., Ruth P., Dostmann W., Sausbier M., Klatt P.Hofmann F., in Rev. Physiol. Biochem. Pharmacol. Berlin / Springer, 135, 105 - 149 (1999), "Structure and Function of cGMP-Dependent Protein Kinases"
  • 14. Muresan S., Bologa C., Mracec M., Chiriac A., Jastorff B., Simon Z.Naray-Szabo G., J. Mol. Struct., 342, 161 - 171 (1995), "Comparative QSAR Study with Electronic and Steric Parameters for cAMP Derivatives with Large Substituents in Positions 2, 6 and 8"
  • 15. Muresan S., Bologa C., Chiriac A., Jastorff B., Kurunczi L.Simon Z., Quant. Struct.-Act. Relat., 13, 242 - 248 (1994), "Comparative Structure-Affinity Relations by MTD for Binding of Cycloadenosine Monophosphate Derivatives to Protein Kinase Receptors"
  • 16. Connolly B. J., Willits P. B., Warrington B. H.Murray K. J., Biochem. Pharmacol., 44, 2303 - 2306 (1992), "8-(4-Chlorophenyl)thio-cyclic AMP is a Potent Inhibitor of the cyclic GMP-specific Phosphodiesterase (PDEV )"
  • 17. Oegreid D., Ekanger R., Suva R. H., Miller J. P.Doeskeland S. O., Eur. J. Biochem., 181, 19 - 31 (1989), "Comparison of the Two Classes of Binding Sites ( A and B ) of Type I and Type II Cyclic AMP-dependent Protein Kinases Using Cyclic Nucleotide Analogs"
  • 18. Oegreid D., Doeskeland S. O.Miller J. P., J. Biol. Chem., 258, 1041 - 1049 (1983), "Evidence That Cyclic Nucleotides Activating Rabbit Muscle Protein Kinase I Interact with Both Types of cAMP Binding Sites Associated with the Enzyme"
  • 19. Hong C. I., Tritsch G. L., Mittelman A., Hebborn P.Chheda G. B., J. Med. Chem., 18, 465 - 473 (1975), "Synthesis and Antitumor Activity of 5'-Phosphates and Cyclic 3', 5' -Phosphates Derived from Biologically Active Nucleosides"